Overview

Comparison of Two Different Doses of STI571 in Treating Patients With Metastatic or Unresectable Gastrointestinal Stromal Tumor

Status:
Terminated

Trial end date:
2014-11-01

Target enrollment:

Participant gender:

Summary

Randomized phase III trial to compare the effectiveness of two different doses of STI571 in treating patients who have metastatic or unresectable gastrointestinal stromal tumor. STI571 may interfere with the growth of tumor cells and may be an effective treatment for cancer. It is not yet known which dose of STI571 is more effective in treating gastrointestinal stromal tumors.

Phase:

Phase 3

Details

Lead Sponsor:

National Cancer Institute (NCI)

Collaborators:

Eastern Cooperative Oncology Group
NCIC Clinical Trials Group
Southwest Oncology Group

Treatments:

Imatinib Mesylate